世界の医薬品用ゼラチン市場:ソース別(豚、牛皮、牛骨、魚、鶏)、用途別、機能別、地域別

【英語タイトル】Pharmaceutical Gelatin Market by Source (Porcine, Bovine Skin, Bovine Bone, Fish, Poultry), Application (Hard Capsule, Soft Capsule, Tablet, Absorbable Hemostat), Function (Stabilizing, Thickening, Gelling), Region - Global Forecast to 2027

MarketsandMarketsが出版した調査資料(PH7750-22)・商品コード:PH7750-22
・発行会社(調査会社):MarketsandMarkets
・発行日:2022年12月10日
・ページ数:190
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥984,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥1,206,200見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

MarketsandMarkets社では、世界の医薬品用ゼラチン市場規模は、2022年11億ドルから2027年15億ドルまで年平均5.5%成長すると予測されています。当調査資料は、医薬品用ゼラチンの世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、用途別(ハードカプセル、ソフトカプセル、錠剤、吸収性止血材、その他)分析、ソース別(豚、牛皮、牛骨、魚、鶏)分析、機能別(安定化剤、増粘剤、ゲル化剤&その他機能)分析、種類別(B型ゼラチン、タイプAゼラチン)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ)分析、競争状況などの項目を掲載しています。なお、当書に掲載されている企業情報には、Darling Ingredients Inc. (US)、Gelita AG (Germany)、Tessenderlo Group (Belgium)、Nitta Gelatin (Japan)、Weishardt (France)、Italgel S.p.A (Italy)、Lapi Gelatine S.p.A (Italy)、India Gelatine & Chemicals Ltd. (India) 、Gelnex (Brazil)、Baotou Dongbao Bio-Tech (China)、Henan Boom Gelatin (China)などが含まれています。

・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要

・世界の医薬品用ゼラチン市場規模:用途別
- ハードカプセルにおける市場規模
- ソフトカプセルにおける市場規模
- 錠剤における市場規模
- 吸収性止血材における市場規模
- その他用途における市場規模

・世界の医薬品用ゼラチン市場規模:ソース別
- 豚由来ゼラチンの市場規模
- 牛皮由来ゼラチンの市場規模
- 牛骨由来ゼラチンの市場規模
- 魚由来ゼラチンの市場規模
- 鶏由来ゼラチンの市場規模

・世界の医薬品用ゼラチン市場規模:機能別
- 安定化剤の市場規模
- 増粘剤の市場規模
- ゲル化剤&その他機能の市場規模

・世界の医薬品用ゼラチン市場規模:種類別
- B型ゼラチンの市場規模
- タイプAゼラチンの市場規模

・世界の医薬品用ゼラチン市場規模:地域別
- 北米の医薬品用ゼラチン市場規模
- ヨーロッパの医薬品用ゼラチン市場規模
- アジア太平洋の医薬品用ゼラチン市場規模
- 中南米の医薬品用ゼラチン市場規模
- 中東/アフリカの医薬品用ゼラチン市場規模

・競争状況
・企業情報

“The global pharmaceutical gelatin market is projected to reach USD 1.5 Billion by 2027 from USD 1.1 Billion in 2022, at a CAGR of 5.5% during the forecast period of 2022-2027.”
Market growth can be attributed to the functional abilities of gelatin which has economic and environmental benefits. However, factors such as increased veganism have driven the demand for vegetarian capsules and are anticipated to restrain the growth of this market during the forecast period.

“Hard capsules segment held dominant share and anticipated to retain its dominance during the forecast period.”
Based on application, the pharmaceutical gelatin market is segmented into hard capsules, softgel capsules, tablets, absorbable hemostats & other applications. The softgel capsules segment is anticipated to grow faster in the pharmaceutical gelatin market during the forecast period. The growth is majorly attributable to the patient-friendly dosage form.

“Fish gelatin is gaining major attention from end users, and this is likely to have a higher impact on the market growth.”
Based on source, the pharmaceutical gelatin market is further segmented into porcine, bovine skin, bovine bone, marine & poultry. The porcine segment held dominant share in pharmaceutical gelatin market in 2021. The dominance of the segment is due to various factors such as short manufacturing cycle and minimal production cost of gelatin from source . The marine segment is also expected to gain a significant share in coming years, owing to various factors such as the launch of novel fish-based gelatin in the market by key market players.

“Stabilizing agent function segment dominated the market in 2021.”
Based on function, the pharmaceutical gelatin market is further segmented into stabilizing agent, thickening agent, gelling agent & other functions. The thickening agent segment is anticipated to grow at a faster pace owing to its increased use in syrups, elixirs, and other liquid dosages.

“Type B segment held a dominant share in 2021”
Based on type, the pharmaceutical gelatin market is further segmented into type A and type B. The type B segment held the largest share of the pharmaceutical gelatin market in 2021. The easier availability of bovine raw material in most regions and less expensive manufacturing processes are some of the factors likely to project the segment growth during the forecast period.

“North America held a dominant share in 2021.”
Geographically, the pharmaceutical gelatin market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2021, North America accounted for the major share in the pharmaceutical gelatin market. The large share of the North American region is due to increased demand for gelatin in the pharmaceutical industry and the presence of a large number of market players in the region. These factors can be attributed to the market growth of the North American region during the forecast period.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type – Supply Side: 70.0%, Demand Side: 30.0%
• By Designation – Managers: 45.0%, CXOs & Directors:30.0%, Excecutives:25.0%
• By Region – North America: 20%, Europe: 10%, Asia Pacific: 55%, Latin America: 10%, Middle East & Africa: 5%

• List of Companies Profiled in the Report
o Darling Ingredients Inc. (US)
o Gelita AG (Germany)
o Tessenderlo Group (Belgium)
o Nitta Gelatin (Japan)
o Weishardt (France)
o Italgel S.p.A (Italy)
o Lapi Gelatine S.p.A (Italy)
o India Gelatine & Chemicals Ltd. (India)
o Gelnex (Brazil)
o Baotou Dongbao Bio-Tech (China)
o Henan Boom Gelatin (China)
o Heibei Chengda Mingjiao (China)
o Kenney & Ross Limited (Canada)
o Narmada Gelatin Limited (India)
o Junca Gelatines (Spain)
o Trobas Gelatine B.V. (Netherlands)
o Jellice Gelatin (Japan)
o Norland Products Inc. (US)
o Xiamen Gelken Gelatin Co. Ltd. (China)
o Athos Collagen (India)
o Geliko LLC (US)
o Reinert Gruppe Ingredients (Germany)
o Gelco International (Brazil)
o Sterling Gelatin (India)
o Geltec (South Korea)

Research Coverage:
This report provides a detailed picture of the global pharmaceutical gelatin market. It aims at estimating the size and future growth potential of the market across different segments, such as application, source, function, type, and region. The report also analyzes factors (such as drivers, restraints, and opportunities) affecting the market growth. It evaluates the opportunities in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total pharmaceutical gelatin market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on pharmaceutical gelatin offered by the top 25 players in the pharmaceutical gelatin market. The report analyses the pharmaceutical gelatin market by application, source, function, type and region.

• Market Development: Comprehensive information about beneficial emerging markets. The report analyzes the markets for various pharmaceutical gelatin products across key geographic regions.

• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the pharmaceutical gelatin market.

• Competitive Assessment: In-depth assessment of market ranking and strategies of the leading players in the pharmaceutical gelatin market.

❖ レポートの目次 ❖

1 INTRODUCTION 28
1.1 STUDY OBJECTIVES 28
1.2 MARKET DEFINITION 28
1.2.1 INCLUSIONS AND EXCLUSIONS 28
1.3 MARKET SCOPE 29
1.3.1 YEARS CONSIDERED 29
1.3.2 CURRENCY CONSIDERED 30
1.4 LIMITATIONS 30
1.5 STAKEHOLDERS 30
1.6 SUMMARY OF CHANGES 30
2 RESEARCH METHODOLOGY 32
2.1 RESEARCH DATA 32
FIGURE 1 RESEARCH DESIGN 32
2.1.1 SECONDARY DATA 33
2.1.2 PRIMARY DATA 33
FIGURE 2 PHARMACEUTICAL GELATIN MARKET: BREAKDOWN OF PRIMARIES 34
2.2 MARKET ESTIMATION METHODOLOGY 35
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 35
FIGURE 3 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 36
FIGURE 4 AVERAGE MARKET SIZE ESTIMATION (2021) 36
2.3 DATA TRIANGULATION APPROACH 38
FIGURE 5 DATA TRIANGULATION METHODOLOGY 38
2.4 GROWTH RATE ASSUMPTIONS 39
2.5 RISK ASSESSMENT 39
2.6 GROWTH FORECAST 39
2.6.1 SUPPLY-SIDE ANALYSIS 39
2.6.1.1 Insights from primary experts 40
3 EXECUTIVE SUMMARY 41
FIGURE 6 PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 41
FIGURE 7 PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2022 VS. 2027 (USD MILLION) 42
FIGURE 8 PHARMACEUTICAL GELATIN MARKET SHARE, BY FUNCTION, 2021 42
FIGURE 9 PHARMACEUTICAL GELATIN MARKET SHARE, BY TYPE, 2021 43
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF PHARMACEUTICAL GELATIN MARKET 44

4 PREMIUM INSIGHTS 45
4.1 PHARMACEUTICAL GELATIN MARKET OVERVIEW 45
FIGURE 11 VERSATILITY OF GELATIN IN PHARMACEUTICAL AND BIOMEDICAL APPLICATIONS TO DRIVE MARKET GROWTH 45
4.2 ASIA PACIFIC: PHARMACEUTICAL GELATIN MARKET SHARE, BY APPLICATION (2021) 46
FIGURE 12 HARD CAPSULES ACCOUNTED FOR LARGEST SHARE IN 2021 46
4.3 PHARMACEUTICAL GELATIN MARKET SHARE, BY SOURCE, 2022 VS. 2027 46
FIGURE 13 PORCINE GELATIN TO DOMINATE MARKET DURING FORECAST PERIOD 46
4.4 PHARMACEUTICAL GELATIN MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 47
FIGURE 14 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS 48
FIGURE 15 PHARMACEUTICAL GELATIN MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48
5.2.1 DRIVERS 49
5.2.1.1 Advantages and properties of gelatin 49
5.2.1.2 Launch of advanced pharma gelatins 49
5.2.1.3 Increasing biomedical applications of gelatin 49
5.2.2 RESTRAINTS 50
5.2.2.1 Cultural restrictions in certain regions 50
5.2.2.2 Shift toward non-gelatin capsules 50
5.2.3 OPPORTUNITIES 50
5.2.3.1 Demand for pharma gelatin in developing countries 50
5.2.3.2 Adoption of gelatin in vaccines and biomedical applications 51
5.2.4 CHALLENGES 51
5.2.4.1 Insufficient raw materials 51
5.2.4.2 Increasing incidence of animal-borne diseases 52
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 52
FIGURE 16 REVENUE SHIFTS AND NEW REVENUE POCKETS FOR PHARMACEUTICAL GELATIN 52
5.4 PRICING ANALYSIS 53
5.4.1 AVERAGE SELLING PRICE TREND 53
TABLE 1 AVERAGE SELLING PRICE OF PHARMACEUTICAL GELATIN, BY REGION 53
5.4.2 INDICATIVE PRICING ANALYSIS, BY MARKET PLAYER 53
TABLE 2 XIAMEN GELKEN GELATIN: AVERAGE SELLING PRICE OF PHARMACEUTICAL GELATIN 53
TABLE 3 HENAN BOOM GELATIN: AVERAGE SELLING PRICE OF PHARMACEUTICAL GELATIN 54
5.5 VALUE CHAIN ANALYSIS 54
FIGURE 17 PHARMACEUTICAL GELATIN MARKET: VALUE CHAIN ANALYSIS 55
5.5.1 SOURCING OF RAW MATERIAL 55
5.5.2 COLLECTION AND TRANSPORT OF RAW MATERIAL 55
5.5.3 RAW MATERIAL PREPARATION AND PROCESSING 55
5.5.4 GELATIN PRODUCTION 55
5.6 ECOSYSTEM ANALYSIS 56
5.6.1 FARMING INPUT 56
5.6.2 FARMING 56
5.6.3 SLAUGHTERING 56
5.6.4 MANUFACTURING 56
5.6.5 SUPPLIERS/DISTRIBUTORS 56
5.6.6 END-PRODUCT MANUFACTURERS 56
FIGURE 18 PHARMACEUTICAL GELATIN MARKET: ECOSYSTEM ANALYSIS 57
5.6.7 ROLE IN ECOSYSTEM 57
5.7 TECHNOLOGY ANALYSIS 57
TABLE 4 PHARMACEUTICAL GELATIN MARKET: TECHNOLOGICAL ADVANCEMENTS, 2019–2022 58
5.8 PATENT ANALYSIS 58
5.8.1 LIST OF MAJOR PATENTS 59
5.9 PORTER’S FIVE FORCES ANALYSIS 60
TABLE 5 PHARMACEUTICAL GELATIN MARKET: PORTER’S FIVE FORCES ANALYSIS 60
5.9.1 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS 61
5.9.2 BARGAINING POWER OF SUPPLIERS 61
5.9.3 BARGAINING POWER OF BUYERS 61
5.9.4 THREAT FROM SUBSTITUTES 61
5.9.5 THREAT FROM NEW ENTRANTS 62
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA 62
FIGURE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PHARMACEUTICAL GELATIN 62
FIGURE 20 KEY BUYING CRITERIA FOR PHARMACEUTICAL GELATIN AMONG END USERS 63
5.11 REGULATORY LANDSCAPE 63
5.11.1 NORTH AMERICA 63
5.11.2 EUROPE 63
5.11.3 ASIA PACIFIC 63
5.11.4 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
TABLE 6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 64
5.12 TRADE ANALYSIS 65
5.12.1 US 65
5.12.2 INDIA 65
TABLE 7 TOP IMPORTERS OF GELATIN FROM INDIA, BY VALUE, 2020-2021 (APR-NOV) 65
5.12.3 BRAZIL 66
5.12.4 OVERVIEW OF GELATIN TRADE/IMPEX, BY COUNTRY 66

5.13 KEY CONFERENCES & EVENTS IN 2022–2023 66
TABLE 8 PHARMACEUTICAL GELATIN MARKET: DETAILED LIST OF EVENTS AND CONFERENCES 66
6 PHARMACEUTICAL GELATIN MARKET, BY APPLICATION 67
6.1 INTRODUCTION 68
TABLE 9 PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 68
6.2 HARD CAPSULES 68
6.2.1 ADVANTAGES OF GELATIN-BASED HARD CAPSULES TO PROPEL MARKET 68
TABLE 10 TYPICAL HARD GELATIN CAPSULE COMPOSITION 69
TABLE 11 DIMENSIONS (IN MILLIMETERS) AND VOLUME (IN MILLIMETERS) OF TWO-PIECE HARD CAPSULES 69
TABLE 12 PHARMACEUTICAL GELATIN MARKET FOR HARD CAPSULES, BY REGION, 2020–2027 (USD MILLION) 70
TABLE 13 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET FOR HARD CAPSULES, BY COUNTRY, 2020–2027 (USD MILLION) 70
TABLE 14 EUROPE: PHARMACEUTICAL GELATIN MARKET FOR HARD CAPSULES, BY COUNTRY, 2020–2027 (USD MILLION) 71
TABLE 15 ASIA PACIFIC: PHARMACEUTICAL GELATIN MARKET FOR HARD CAPSULES, BY COUNTRY, 2020–2027 (USD MILLION) 71
6.3 SOFTGEL CAPSULES 71
6.3.1 RISING DEMAND FOR SOFTGEL CAPSULES IN PHARMA INDUSTRY TO DRIVE GROWTH 71
TABLE 16 DIFFERENCES BETWEEN HARD CAPSULES AND SOFTGEL CAPSULES 72
TABLE 17 PHARMACEUTICAL GELATIN MARKET FOR SOFTGEL CAPSULES, BY REGION, 2020–2027 (USD MILLION) 73
TABLE 18 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET FOR SOFTGEL CAPSULES, BY COUNTRY, 2020–2027 (USD MILLION) 73
TABLE 19 EUROPE: PHARMACEUTICAL GELATIN MARKET FOR SOFTGEL CAPSULES, BY COUNTRY, 2020–2027 (USD MILLION) 73
TABLE 20 ASIA PACIFIC: PHARMACEUTICAL GELATIN MARKET FOR SOFTGEL CAPSULES, BY COUNTRY, 2020–2027 (USD MILLION) 74
6.4 TABLETS 74
6.4.1 USE OF GELATIN AS BINDERS IN TABLETS TO CONTRIBUTE TO SEGMENTAL GROWTH 74
TABLE 21 IN VITRO PROPERTIES OF TABLETS WITH GELATIN AS BINDER (CONCENTRATIONS 2.0-8.0%) 74
TABLE 22 PHARMACEUTICAL GELATIN MARKET FOR TABLETS, BY REGION, 2020–2027 (USD MILLION) 75
TABLE 23 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET FOR TABLETS, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 24 EUROPE: PHARMACEUTICAL GELATIN MARKET FOR TABLETS, BY COUNTRY, 2020–2027 (USD MILLION) 75
TABLE 25 ASIA PACIFIC: PHARMACEUTICAL GELATIN MARKET FOR TABLETS, BY COUNTRY, 2020–2027 (USD MILLION) 76

6.5 ABSORBABLE HEMOSTATS 76
6.5.1 INCREASED ADOPTION OF ABSORBABLE HEMOSTATS TO DRIVE MARKET 76
TABLE 26 PHARMACEUTICAL GELATIN MARKET FOR ABSORBABLE HEMOSTATS, BY REGION, 2020–2027 (USD MILLION) 77
TABLE 27 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET FOR ABSORBABLE HEMOSTATS, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 28 EUROPE: PHARMACEUTICAL GELATIN MARKET FOR ABSORBABLE HEMOSTATS, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 29 ASIA PACIFIC: PHARMACEUTICAL GELATIN MARKET FOR ABSORBABLE HEMOSTATS, BY COUNTRY, 2020–2027 (USD MILLION) 78
6.6 OTHER APPLICATIONS 78
TABLE 30 PHARMACEUTICAL GELATIN MARKET FOR OTHER APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 79
TABLE 31 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 79
TABLE 32 EUROPE: PHARMACEUTICAL GELATIN MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 80
TABLE 33 ASIA PACIFIC: PHARMACEUTICAL GELATIN MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 80
7 PHARMACEUTICAL GELATIN MARKET, BY SOURCE 81
7.1 INTRODUCTION 82
TABLE 34 AMINO ACID COMPOSITION OF GELATINS, BY SOURCE 82
TABLE 35 PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 82
TABLE 36 PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (KT) 83
7.2 PORCINE 83
7.2.1 LOWER MANUFACTURING COSTS OF PORCINE RAW MATERIALS TO PROPEL MARKET GROWTH 83
TABLE 37 US: PORK EXPORTS IN USD MILLION (2017-2021) 84
TABLE 38 PORCINE PHARMACEUTICAL GELATIN MARKET, BY REGION, 2020–2027 (USD MILLION) 84
TABLE 39 NORTH AMERICA: PORCINE PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 40 EUROPE: PORCINE PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 85
TABLE 41 ASIA PACIFIC: PORCINE PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 85
7.3 BOVINE SKIN 86
7.3.1 INCREASING AVAILABILITY OF BOVINE SKIN TO BOOST GROWTH 86
TABLE 42 BOVINE SKIN PHARMACEUTICAL GELATIN MARKET, BY REGION, 2020–2027 (USD MILLION) 86
TABLE 43 NORTH AMERICA: BOVINE SKIN PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86
TABLE 44 EUROPE: BOVINE SKIN PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 87
TABLE 45 ASIA PACIFIC: BOVINE SKIN PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 87
7.4 BOVINE BONE 87
7.4.1 ADVANTAGES OF BOVINE BONE LIKELY TO SUPPORT DEMAND GROWTH 87
TABLE 46 BOVINE BONE PHARMACEUTICAL GELATIN MARKET, BY REGION, 2020–2027 (USD MILLION) 88
TABLE 47 NORTH AMERICA: BOVINE BONE PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 88
TABLE 48 EUROPE: BOVINE BONE PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 89
TABLE 49 ASIA PACIFIC: BOVINE BONE PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 89
7.5 MARINE 89
7.5.1 INCIDENCE OF ZOONOTIC DISEASES IN CATTLE AND PIGS TO DRIVE DEMAND FOR MARINE GELATIN 89
TABLE 50 MARINE PHARMACEUTICAL GELATIN MARKET, BY REGION, 2020–2027 (USD MILLION) 90
TABLE 51 NORTH AMERICA: MARINE PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 90
TABLE 52 EUROPE: MARINE PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 91
TABLE 53 ASIA PACIFIC: MARINE PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 91
7.6 POULTRY 91
7.6.1 AVAILABILITY OF POULTRY AS A RAW MATERIAL TO BOOST UTILITY 91
TABLE 54 POULTRY PHARMACEUTICAL GELATIN MARKET, BY REGION, 2020–2027 (USD MILLION) 92
TABLE 55 NORTH AMERICA: POULTRY PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 92
TABLE 56 EUROPE: POULTRY PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 57 ASIA PACIFIC: POULTRY PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 93
8 PHARMACEUTICAL GELATIN MARKET, BY FUNCTION 94
8.1 INTRODUCTION 95
TABLE 58 PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 95
8.2 STABILIZING AGENTS 95
8.2.1 RISING VACCINE AND CAPSULE PRODUCTION TO DRIVE DEMAND FOR STABILIZING AGENTS 95
TABLE 59 PHARMACEUTICAL GELATIN MARKET FOR STABILIZING AGENTS, BY REGION, 2020–2027 (USD MILLION) 96
TABLE 60 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET FOR STABILIZING AGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 61 EUROPE: PHARMACEUTICAL GELATIN MARKET FOR STABILIZING AGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 97
TABLE 62 ASIA PACIFIC: PHARMACEUTICAL GELATIN MARKET FOR STABILIZING AGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 97
8.3 THICKENING AGENTS 97
8.3.1 GROWING USE OF GELATIN IN SYRUPS AND LIQUID DOSAGE FORMS TO DRIVE MARKET 97
TABLE 63 PHARMACEUTICAL GELATIN MARKET FOR THICKENING AGENTS, BY REGION, 2020–2027 (USD MILLION) 98
TABLE 64 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET FOR THICKENING AGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 65 EUROPE: PHARMACEUTICAL GELATIN MARKET FOR THICKENING AGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 99
TABLE 66 ASIA PACIFIC: PHARMACEUTICAL GELATIN MARKET FOR THICKENING AGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 99
8.4 GELLING AGENTS & OTHER FUNCTIONS 99
8.4.1 WIDE APPLICATIONS IN SOFTGEL CAPSULES AND HEMOSTATS TO BOOST DEMAND FOR GELLING AGENTS 99
TABLE 67 PHARMACEUTICAL GELATIN MARKET FOR GELLING AGENTS & OTHER FUNCTIONS, BY REGION, 2020–2027 (USD MILLION) 100
TABLE 68 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET FOR GELLING AGENTS & OTHER FUNCTIONS, BY COUNTRY, 2020–2027 (USD MILLION) 100
TABLE 69 EUROPE: PHARMACEUTICAL GELATIN MARKET FOR GELLING AGENTS & OTHER FUNCTIONS, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 70 ASIA PACIFIC: PHARMACEUTICAL GELATIN MARKET FOR GELLING AGENTS & OTHER FUNCTIONS, BY COUNTRY, 2020–2027 (USD MILLION) 101
9 PHARMACEUTICAL GELATIN MARKET, BY TYPE 102
9.1 INTRODUCTION 103
TABLE 71 PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 103
9.2 TYPE B GELATIN 103
9.2.1 INCREASED DEMAND FOR BOVINE-BASED GELATIN TO PROPEL MARKET GROWTH 103
TABLE 72 NUTRITIONAL COMPOSITION OF TYPE B GELATIN 103
TABLE 73 TYPE B PHARMACEUTICAL GELATIN MARKET, BY REGION, 2020–2027 (USD MILLION) 104
TABLE 74 NORTH AMERICA: TYPE B PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 75 EUROPE: TYPE B PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 105
TABLE 76 ASIA PACIFIC: TYPE B PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 105
9.3 TYPE A GELATIN 105
9.3.1 COST-EFFECTIVENESS OF PROCESSING TYPE A GELATIN TO DRIVE GROWTH 105
TABLE 77 NUTRITIONAL COMPOSITION OF TYPE A GELATIN 106
TABLE 78 TYPE A PHARMACEUTICAL GELATIN MARKET, BY REGION, 2020–2027 (USD MILLION) 106
TABLE 79 NORTH AMERICA: TYPE A PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 107
TABLE 80 EUROPE: TYPE A PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 107
TABLE 81 ASIA PACIFIC: TYPE A PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 107
10 PHARMACEUTICAL GELATIN MARKET, BY REGION 108
10.1 INTRODUCTION 109
TABLE 82 PHARMACEUTICAL GELATIN MARKET, BY REGION, 2020–2027 (USD MILLION) 109
10.2 NORTH AMERICA 109
FIGURE 21 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET SNAPSHOT 110
TABLE 83 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 84 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 111
TABLE 85 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 111
TABLE 86 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 112
TABLE 87 NORTH AMERICA: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
10.2.1 US 112
10.2.1.1 Increased prevalence of chronic diseases to drive market 112
TABLE 88 US: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 113
TABLE 89 US: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 113
TABLE 90 US: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 114
TABLE 91 US: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 114
10.2.2 CANADA 114
10.2.2.1 Increasing demand for biopharmaceuticals to support growth 114
TABLE 92 CANADA: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 115
TABLE 93 CANADA: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 115
TABLE 94 CANADA: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 115
TABLE 95 CANADA: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 116
10.3 EUROPE 116
TABLE 96 EUROPE: PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 117
TABLE 97 EUROPE: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 117
TABLE 98 EUROPE: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 118
TABLE 99 EUROPE: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 118
TABLE 100 EUROPE: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 118
10.3.1 GERMANY 119
10.3.1.1 Rising focus and investment in pharmaceutical R&D to promote market growth 119
TABLE 101 GERMANY: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 119
TABLE 102 GERMANY: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 120
TABLE 103 GERMANY: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 120
TABLE 104 GERMANY: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 120
10.3.2 UK 121
10.3.2.1 Investments in novel drug development to propel demand for pharmaceutical gelatin 121
TABLE 105 UK: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 106 UK: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 121
TABLE 107 UK: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 122
TABLE 108 UK: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 122
10.3.3 FRANCE 122
10.3.3.1 Increased investment in pharmaceutical R&D to drive demand for pharmaceutical gelatin 122
TABLE 109 FRANCE: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 123
TABLE 110 FRANCE: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 123
TABLE 111 FRANCE: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 124
TABLE 112 FRANCE: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 124
10.3.4 ITALY 124
10.3.4.1 Pharma R&D and innovation efforts to boost gelatin usage 124
TABLE 113 ITALY: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 125
TABLE 114 ITALY: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 125
TABLE 115 ITALY: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 125
TABLE 116 ITALY: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 126
10.3.5 SPAIN 126
10.3.5.1 Growing pharma manufacturing to fuel demand for gelatin 126
TABLE 117 SPAIN: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 126
TABLE 118 SPAIN: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 127
TABLE 119 SPAIN: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 127
TABLE 120 SPAIN: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 127
10.3.6 REST OF EUROPE 128
TABLE 121 ROE: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 122 ROE: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 128
TABLE 123 ROE: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 129
TABLE 124 ROE: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 129
10.4 ASIA PACIFIC 129
FIGURE 22 ASIA PACIFIC: PHARMACEUTICAL GELATIN MARKET SNAPSHOT 130
TABLE 125 ASIA PACIFIC: PHARMACEUTICAL GELATIN MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 131
TABLE 126 ASIA PACIFIC: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 127 ASIA PACIFIC: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 132
TABLE 128 ASIA PACIFIC: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 132
TABLE 129 ASIA PACIFIC: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 132
10.4.1 JAPAN 133
10.4.1.1 Increasing aging population to create growth opportunities 133
TABLE 130 JAPAN: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 133
TABLE 131 JAPAN: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 133
TABLE 132 JAPAN: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 134
TABLE 133 JAPAN: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 134
10.4.2 CHINA 134
10.4.2.1 Large population and availability of raw materials to contribute to market growth in China 134
TABLE 134 CHINA: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 135
TABLE 135 CHINA: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 135
TABLE 136 CHINA: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 135
TABLE 137 CHINA: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 136
10.4.3 INDIA 136
10.4.3.1 Booming pharmaceutical industry to drive market 136
TABLE 138 INDIA: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 136
TABLE 139 INDIA: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 137
TABLE 140 INDIA: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 137
TABLE 141 INDIA: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 137
10.4.4 REST OF ASIA PACIFIC 138
TABLE 142 ROAPAC: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 138
TABLE 143 ROAPAC: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 139
TABLE 144 ROAPAC: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 139
TABLE 145 ROAPAC: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 139
10.5 LATIN AMERICA 140
10.5.1 RISING DEMAND FOR PHARMA GELATIN IN LATIN AMERICA TO DRIVE MARKET GROWTH 140
TABLE 146 LATAM: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 140
TABLE 147 LATAM: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 141
TABLE 148 LATAM: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 141
TABLE 149 LATAM: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 141
10.6 MIDDLE EAST & AFRICA 142
10.6.1 RISING ADOPTION OF GELATIN-BASED PHARMA PRODUCTS TO PROPEL GROWTH 142
TABLE 150 MEA: PHARMACEUTICAL GELATIN MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 151 MEA: PHARMACEUTICAL GELATIN MARKET, BY SOURCE, 2020–2027 (USD MILLION) 143
TABLE 152 MEA: PHARMACEUTICAL GELATIN MARKET, BY FUNCTION, 2020–2027 (USD MILLION) 143
TABLE 153 MEA: PHARMACEUTICAL GELATIN MARKET, BY TYPE, 2020–2027 (USD MILLION) 143

11 COMPETITIVE LANDSCAPE 144
11.1 INTRODUCTION 144
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 144
FIGURE 23 PHARMACEUTICAL GELATIN MARKET: STRATEGIES ADOPTED 144
11.3 REVENUE ANALYSIS 145
FIGURE 24 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021) 145
11.4 MARKET SHARE ANALYSIS 145
FIGURE 25 PHARMACEUTICAL GELATIN MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021 145
TABLE 154 PHARMACEUTICAL GELATIN MARKET: DEGREE OF COMPETITION 146
11.5 COMPANY EVALUATION QUADRANT 147
11.5.1 STARS 147
11.5.2 EMERGING LEADERS 147
11.5.3 PERVASIVE PLAYERS 147
11.5.4 PARTICIPANTS 147
FIGURE 26 PHARMACEUTICAL GELATIN MARKET: COMPANY EVALUATION QUADRANT, 2021 148
11.6 COMPANY EVALUATION QUADRANT FOR SMES/START-UPS (2021) 149
11.6.1 PROGRESSIVE COMPANIES 149
11.6.2 STARTING BLOCKS 149
11.6.3 RESPONSIVE COMPANIES 149
11.6.4 DYNAMIC COMPANIES 149
FIGURE 27 PHARMACEUTICAL GELATIN MARKET: COMPANY EVALUATION QUADRANT FOR SMES/START-UPS, 2021 150
11.7 COMPETITIVE BENCHMARKING 151
TABLE 155 OVERALL COMPANY FOOTPRINT 151
TABLE 156 COMPANY PRODUCT FOOTPRINT 152
TABLE 157 COMPANY REGIONAL FOOTPRINT 153
11.8 COMPETITIVE SCENARIO AND TRENDS 154
TABLE 158 PHARMACEUTICAL GELATIN MARKET: PRODUCT LAUNCHES, JANUARY 2019–OCTOBER 2022 154
TABLE 159 PHARMACEUTICAL GELATIN MARKET: DEALS, JANUARY 2019–OCTOBER 2022 154
TABLE 160 PHARMACEUTICAL GELATIN MARKET: OTHER DEVELOPMENTS, JANUARY 2019–OCTOBER 2022 155

12 COMPANY PROFILES 156
12.1 KEY PLAYERS 156
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DARLING INGREDIENTS 156
TABLE 161 DARLING INGREDIENTS: BUSINESS OVERVIEW 156
FIGURE 28 DARLING INGREDIENTS: COMPANY SNAPSHOT (2022) 157
12.1.2 NITTA GELATIN 160
TABLE 162 NITTA GELATIN: BUSINESS OVERVIEW 160
FIGURE 29 NITTA GELATIN: COMPANY SNAPSHOT (2022) 161
12.1.3 TESSENDERLO GROUP 162
TABLE 163 TESSENDERLO GROUP: BUSINESS OVERVIEW 162
FIGURE 30 TESSENDERLO GROUP: COMPANY SNAPSHOT (2022) 163
12.1.4 GELITA AG 165
TABLE 164 GELITA AG: BUSINESS OVERVIEW 165
12.1.5 WEISHARDT 168
TABLE 165 WEISHARDT: BUSINESS OVERVIEW 168
12.1.6 TROBAS GELATINE 169
TABLE 166 TROBAS GELATINE: BUSINESS OVERVIEW 169
12.1.7 LAPI GELATINE 170
TABLE 167 LAPI GELATINE S.P.A: BUSINESS OVERVIEW 170
12.1.8 INDIA GELATINE & CHEMICALS 172
TABLE 168 INDIA GELATINE & CHEMICALS: BUSINESS OVERVIEW 172
FIGURE 31 INDIA GELATINE & CHEMICALS: COMPANY SNAPSHOT (2022) 172
12.1.9 GELNEX 173
TABLE 169 GELNEX: BUSINESS OVERVIEW 173
12.1.10 JUNCA GELATINES 174
TABLE 170 JUNCA GELATINES: BUSINESS OVERVIEW 174
12.1.11 HEBEI CHENGDA MINGJIAO 175
TABLE 171 HEBEI CHENGDA MINGJIAO: BUSINESS OVERVIEW 175
12.1.12 ITALGEL 176
TABLE 172 ITALGEL: BUSINESS OVERVIEW 176
12.1.13 XIAMEN GELKEN GELATIN 177
TABLE 173 XIAMEN GELKEN GELATIN BUSINESS OVERVIEW 177
12.1.14 GELCO INTERNATIONAL 178
TABLE 174 GELCO INTERNATIONAL: BUSINESS OVERVIEW 178
12.1.15 HENAN BOOM GELATIN 179
TABLE 175 HENAN BOOM GELATIN: BUSINESS OVERVIEW 179
12.1.16 NORLAND PRODUCTS 180
TABLE 176 NORLAND PRODUCTS: BUSINESS OVERVIEW 180
12.1.17 GELIKO 181
TABLE 177 GELIKO: BUSINESS OVERVIEW 181
12.1.18 KENNEY & ROSS LIMITED 182
TABLE 178 KENNEY & ROSS LIMITED: BUSINESS OVERVIEW 182
12.1.19 BAOTOU DONGBAO BIO-TECH 183
TABLE 179 BAOTOU DONGBAO BIO-TECH: BUSINESS OVERVIEW 183
12.1.20 GELTEC 184
TABLE 180 GELTEC: BUSINESS OVERVIEW 184
12.1.21 NARMADA GELATINES. 185
TABLE 181 NARMADA GELATINES: BUSINESS OVERVIEW 185
FIGURE 32 NARMADA GELATINES: COMPANY SNAPSHOT (2022) 185
12.1.22 REINERT GRUPPE INGREDIENTS GMBH 186
TABLE 182 REINERT GRUPPE INGREDIENTS GMBH: BUSINESS OVERVIEW 186
12.1.23 JELLICE GELATIN & COLLAGEN 187
TABLE 183 JELLICE GELATIN AND COLLAGEN: BUSINESS OVERVIEW 187
12.1.24 STERLING GELATIN 188
TABLE 184 STERLING GELATIN: BUSINESS OVERVIEW 188
12.1.25 ATHOS COLLAGEN 189
TABLE 185 ATHOS COLLAGEN: BUSINESS OVERVIEW 189
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 190
13.1 DISCUSSION GUIDE 190
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 193
13.3 CUSTOMIZATION OPTIONS 195
13.4 RELATED REPORTS 195
13.5 AUTHOR DETAILS 196



★調査レポート[世界の医薬品用ゼラチン市場:ソース別(豚、牛皮、牛骨、魚、鶏)、用途別、機能別、地域別] (コード:PH7750-22)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の医薬品用ゼラチン市場:ソース別(豚、牛皮、牛骨、魚、鶏)、用途別、機能別、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆